· Published by Health Canada · Official notice
These products are not authorized for sale in Canada and have not been found in the Canadian marketplace, but it is possible they may have been brought into the country by travellers or purchased over the Internet.
U.S. Food and Drug Administration (FDA)
Levemir insulin: Lot numbers XZF0036, XZF0037, and XZF0038
Novo Nordisk Inc., Princeton, New Jersey, USA
Levemir insulin is used to treat type 1 diabetes in adults and children, and type 2 diabetes in adults who require long-acting insulin to control high blood sugar.
The product, which is administered by injection, is packaged in 10 ml vials.
The FDA warned consumers not to buy or use three lots of Levemir insulin vials (lot numbers XZF0036, XZF0037, and XZF0038). These lots, which were reported stolen in the U.S., have reappeared for sale on the U.S. market. The three lots, totalling 129,000 vials, may not have been stored and handled properly and may pose a serious risk to health.
The FDA has received one report of a patient who suffered an adverse event due to poor control of blood sugar levels after using a vial from one of these three lots.
The FDA is advising U.S. consumers to:
Canadians who have this product are advised not to use it, and should consult with a health care professional if they have concerns about their health related to the use of this product.
Health Canada advises Canadians to contact the Health Products and Food Branch Inspectorate at 1-800-267-9675 if they find the product listed above in the Canadian marketplace.
Drugs and natural health products that are authorized for sale in Canada will have either an eight-digit Drug Identification Number (DIN), a Natural Product Number (NPN) or a Homeopathic Medicine Number (DIN-HM) on the label. These numbers indicate that the products have been assessed by Health Canada for safety, effectiveness and quality.
As of the date of this posting, no adverse reactions suspected to be associated with the use of this product have been reported in Canada.